In late September, 80 rheumatologists, rheumatology professionals and patients living with rheumatic disease convened in Washington, D.C., for the ACR’s annual Advocates for Arthritis conference, where they marshaled in support of legislation that would reduce current barriers to care for patients.
On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).
Rheumatology giant Frederick Wolfe, MD, passed away Sept. 5, 2023, in Wichita, Kan. The rheumatology community mourns his loss. Fred was born July 1, 1936, in New York. He graduated from Queens College, N.Y., in 1958, and was a social worker for several years. He earned his medical degree in 1966 from the State University…
In this premiere episode, Dr. Kumar discusses what’s new at The Rheumatologist, the deliberate approach we’ve taken to a redesign and how rheumatologists can incorporate human-centered design thinking into their practices.
Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.
The accepted wisdom is that the negative effects of glucocorticoids on bone depend on the dose and treatment duration. Adami et al. conducted this study to determine, in a real-life setting, the risk of fragility fracture associated with the dose of glucocorticoids in patients with inflammatory rheumatic musculoskeletal diseases.
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue and pain than patients who received placebo.
The new resource offers standardized outcome measures for providers who treat patients with RA, as well as training materials for medical staff to guide accurate and efficient data collection. It also includes video tutorials and sample workflows for different EHR systems.
The Insurance Subcommittee is working to address coverage and reimbursement challenges facing rheumatology practices. Recent activities include efforts to avoid increased administrative burden associated with specialty medications, support payer coverage of musculoskeletal ultrasounds and protect patient access to biologics.
Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.